Quartic.ai partners with Sparta Systems to bring forward next-level AI capabilities for early risk detection during the manufacturing process

Life science and data technology innovator, Aigenpulse, is introducing a new state of-the-art data intelligence platform which is designed to expedite the drug discovery and development process. The Aigenpulse platform harnesses the latest artificial intelligence and machine learning tools to deliver advanced analytics to underpin scientific decision making.

Cambridge, UK, 19 June 2020 - OKRA, a leading provider of Artificial Intelligence (AI) driven analytics for Life Sciences, today hit an important milestone, delivering 2 million validated predictions so far in 2020, smashing through its yearly target in just half the expected time. This underscores OKRA’s achievements in empowering the pharmaceutical industry with explainable, real-time AI solutions.

Owkin is a French-American startup, backed by Google Ventures among others, that deploys Artificial Intelligence (AI) and Federated Learning for medical research. The company was co-founded in 2016 by Thomas Clozel, a hematologist oncologist and researcher, and Gilles Wainrib, a computer science teacher-researcher at the École Normale Supérieure, and a Stanford University PostDoc.

Over the years, the team at Owkin has developed AI systems to analyze and interpret multimodal medical data, including pathology images, radiology images, genetic data, lab analysis, and clinical outcomes. The company recently announced the launch of a new product -- Virtual Staining, integrated as a feature in Owkin Studio platform.

Generative models have become one of the hottest areas in de-novo molecular design over just several years, basically revolutionizing our perception of what can be done with artificial intelligence in this area. One important aspect of generative models is that they can produce new quality hit molecules using combined data from various experimental and theoretical sources -- and output results rapidly. 

One notable drug discovery startup betting on deep learning and generative models for innovative drug design is Vancouver-based Variational AI.